Early Detection Research Network

EDRN Breast and Ovary Cancer CVC, Study 3: Phase 3 Validation of screening decision rules in preclinical UKCTOCS serial samples

CVC Study 3
373

No coordinating investigator defined.

CA125, HE4, MSLN, MMP7
No design specified.
Proteomics
Breast and Gynecologic Cancers Research Group
3

To validate specific screening decision rules in preclinical serial samples from the UKCTOCS trial.

1.   Using PLCO preclinical serial samples, we will optimize a serum marker decision rule using CA125, HE4, MSLN, & MMP7 to select women for surgical consult, additional testing, or early recall. 2.   Using UKCTOCS preclinical samples, we will validate the serum marker decision rule developed in Aim 1 using CA125, HE4, MSLN, & MMP7 to select women for surgical consult or additional testing. 3.   Using UKCTOCS preclinical samples we will validate HE4 as a second-line screen in a screening strategy that uses rising CA125 to select women for additional testing.
ROC curves; logistic regression

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.